The present invention relates to a nucleic acid molecule for use in the treatment or preventive treatment of a patient after stent implantation or balloon dilatation, wherein the nucleic acid molecule is selected from (a) a single-stranded nucleic acid molecule comprising or consisting of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4 (b) a hairpin RNA, wherein one of the regions forming the double-stranded portion of said hairpin RNA comprises or consists of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4 (c) an at least partially double-stranded RNA comprising two separate single strands, wherein a region within one of the strands, said region being located within the double-stranded portion of said double-stranded RNA, comprises or consists of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4 (d) a nucleic acid molecule encoding the nucleic acid molecule of (a) or the RNA (b) and (e) a nucleic acid molecule or a two nucleic acid molecules encoding the two separate single strands of the RNA of (c). The present invention also relates to a drug eluting stent comprising the nucleic acid molecule according to the invention.La présente invention concerne une molécule dacide nucléique pour utilisation dans le traitement ou le traitement préventif dun patient après implantation de stent ou dilatation au ballonnet, où la molécule dacide nucléique est choisie parmi (a) une molécule dacide nucléique monocaténaire comprenant ou constituée de la séquence de SEQ ID NO: 1, 2, 3 ou 4 ou dune séquence ayant au moins 90 % didentité de séquence avec la séquence de SEQ ID NO: 1, 2, 3 ou 4 (b) un ARN en épingle à cheveux, où lune des régions formant la partie bicaténaire dudit ARN en épingle à cheveux comprend ou est cons
